Maria Verdugo

4.7k total citations
27 papers, 1.2k citations indexed

About

Maria Verdugo is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Maria Verdugo has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 13 papers in Pathology and Forensic Medicine and 11 papers in Hematology. Recurrent topics in Maria Verdugo's work include Chronic Lymphocytic Leukemia Research (21 papers), Lymphoma Diagnosis and Treatment (11 papers) and Advanced Breast Cancer Therapies (8 papers). Maria Verdugo is often cited by papers focused on Chronic Lymphocytic Leukemia Research (21 papers), Lymphoma Diagnosis and Treatment (11 papers) and Advanced Breast Cancer Therapies (8 papers). Maria Verdugo collaborates with scholars based in United States, Australia and France. Maria Verdugo's co-authors include Jalaja Potluri, Matthew S. Davids, William G. Wierda, Lang Zhou, Steven Coutré, Brenda Chyla, Ahmed Hamed Salem, Michael Y. Choi, Rod Humerickhouse and Richard R. Furman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Maria Verdugo

26 papers receiving 1.2k citations

Peers

Maria Verdugo
Comparison fields: 5 of 45
  • Genetics 861
  • Pathology and Forensic Medicine 599
  • Hematology 520
  • Molecular Biology 356
  • Oncology 271
Replace Mehrdad Mobasher with:
Mehrdad Mobasher United States
Kathryn Humphrey United Kingdom
John N. Allan United States
James D’Rozario Australia
Sissy Peterman United States
Virginia Kelly United States
Margaret S. Lucas United States
Stephanie A. Smoley United States
Anna‐Maria Fink Germany
Alice Lynn United States
Mehrdad Mobasher United States View profile →
Citations per field, relative to Maria Verdugo
Maria Verdugo · 1×
Citations per year, relative to Maria Verdugo
Maria Verdugo · 1×

Countries citing papers authored by Maria Verdugo

Since Specialization
Citations

This map shows the geographic impact of Maria Verdugo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Verdugo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Verdugo more than expected).

Fields of papers citing papers by Maria Verdugo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Verdugo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Verdugo. The network helps show where Maria Verdugo may publish in the future.

Co-authorship network of co-authors of Maria Verdugo

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Verdugo. A scholar is included among the top collaborators of Maria Verdugo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Verdugo. Maria Verdugo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy
2019 ·Haematologica ·(unknown), William G. Wierda, Matthew S. Davids, Bruce D. Cheson, Steven Coutré, Michael Y. Choi, Richard R. Furman, Leonard T. Heffner, Paul M. Barr, Herbert Eradat, (unknown), Lang Zhou, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, John C. Byrd
28
2
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
2019 ·Blood ·Andrew W. Roberts, Shuo Ma, Thomas J. Kipps, Steven Coutré, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, John C. Byrd, Kathryn Humphrey, Lang Zhou, Brenda Chyla, (unknown), Jalaja Potluri, Su Young Kim, Maria Verdugo, Stephan Stilgenbauer, William G. Wierda, John F. Seymour
119
3
Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies
2018 ·Future Oncology ·Andrew E. Place, Kelly C. Goldsmith, Jean‐Pierre Bourquin, Mignon L. Loh, Lia Gore, Daniel A. Morgenstern, Yeshwant D. Sanzgiri, David Hoffman, Ying Zhou, Jeremy A. Ross, Betty Prine, Mohamad Shebley, (unknown), Thalia A. Farazi, Su Young Kim, Maria Verdugo, (unknown), C. Michel Zwaan, Josef Vormoor
39
4
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
2018 ·Annals of Oncology ·Sven de Vos, L. J. Swinnen, Dee Dee Wang, Erin Reid, Nicole Fowler, Jaclyn Cordero, Martin Dunbar, Sari H. Enschede, Cathy E. Nolan, Adam M. Petrich, Jeremy A. Ross, Ahmed Hamed Salem, Maria Verdugo, Suresh Agarwal, Lang Zhou, Mark Kozloff, Loretta J. Nastoupil, Christopher R. Flowers
51
5
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
2018 ·Blood ·Steven Coutré, Michael Y. Choi, Richard R. Furman, Herbert Eradat, Leonard T. Heffner, Jeffrey A. Jones, Brenda Chyla, Lang Zhou, Suresh Agarwal, (unknown), Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, William G. Wierda, Matthew S. Davids
86
6
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
2018 ·Journal of Clinical Oncology ·Arnon P. Kater, John F. Seymour, Peter Hillmen, Barbara Eichhorst, Anton W. Langerak, Carolyn Owen, Maria Verdugo, Jenny Wu, Elizabeth A. Punnoose, Yanwen Jiang, Jue Wang, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Thomas J. Kipps
198
7
Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.
2018 ·Journal of Clinical Oncology ·Thomas Alexander, Seong Lin Khaw, Jeffrey E. Rubnitz, (unknown), Norman J. Lacayo, Michelle Schmidt, Bo Tong, (unknown), (unknown), Maria Verdugo, Su Young Kim, Elias Jabbour, Wendy Stock
1
8
Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)
2017 ·Blood ·William G. Wierda, Matthew S. Davids, Richard R. Furman, Bruce D. Cheson, Paul M. Barr, Herbert Eradat, Leonard T. Heffner, Jeffrey A. Jones, Lang Zhou, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, Michael Y. Choi
3
9
Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma
2017 ·Blood ·Jonathan L. Kaufman, Cristina Gasparetto, Joseph Mıkhael, Philippe Moreau, Cyrille Touzeau, Ravi Vij, Thierry Façon, Brigitte Pegourié, Lofti Benboubker, Lawrence Boise, Stefanie Alzate, Martin Dunbar, Jia Jia, Kevin J. Freise, Maria Verdugo, Jeremy A. Ross, Paulo Maciag, Shaji Kumar
12
10
Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy
2017 ·Blood ·Anthony R. Mato, William G. Wierda, Matthew S. Davids, Bruce D. Cheson, Steven Coutré, Michael Y. Choi, Richard R. Furman, Leonard T. Heffner, Paul M. Barr, Herbert Eradat, Lang Zhou, Maria Verdugo, Jalaja Potluri, Jeffrey A. Jones
12
11
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
2017 ·The Lancet Oncology ·Jeffrey A. Jones, Anthony R. Mato, William G. Wierda, Matthew S. Davids, Michael Y. Choi, Bruce D. Cheson, Richard R. Furman, Nicole Lamanna, Paul M. Barr, Lang Zhou, Brenda Chyla, Ahmed Hamed Salem, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, Steven Coutré, Jennifer A. Woyach, John C. Byrd
262
12
A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
2017 ·Clinical Lymphoma Myeloma & Leukemia ·Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts, Amit B. Agarwal, Thierry Façon, Shaji Kumar, Cyrille Touzeau, Jaclyn Cordero, Jeremy A. Ross, Wijith Munasinghe, Jia Jia, Ahmed Hamed Salem, Joel Johansson, Paulo Maciag, Maria Verdugo, Simon J. Harrison
0
13
Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
2017 ·Journal of Clinical Oncology ·Matthew S. Davids, Andrew W. Roberts, John F. Seymour, William G. Wierda, Soham D. Puvvada, Lori A. Gressick, (unknown), Lang Zhou, Su Young Kim, Maria Verdugo, John F. Gerecitano
1
14
VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON‐HODGKIN LYMPHOMA (NHL)
2017 ·Hematological Oncology ·Matthew S. Davids, Andrew W. Roberts, John F. Seymour, William G. Wierda, Soham D. Puvvada, Lori A. Gressick, (unknown), Martin Dunbar, Lang Zhou, (unknown), Maria Verdugo, John F. Gerecitano
3
15
Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma
2016 ·Blood ·Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts, Amit B. Agarwal, Thierry Façon, Shaji Kumar, Cyrille Touzeau, Jaclyn Cordero, Jeremy A. Ross, Wijith Munasinghe, Jia Jia, Ahmed Hamed Salem, Joel Johansson, Paulo Maciag, Maria Verdugo, Simon J. Harrison
18
16
Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
2016 ·Blood ·Danielle M. Brander, Michael Y. Choi, Andrew W. Roberts, Shuo Ma, (unknown), Maria Verdugo, Ming Zhu, Su Young Kim, John F. Seymour
4
17
Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia
2016 ·Blood ·John F. Seymour, Matthew S. Davids, Andrew W. Roberts, Michael Hallek, William G. Wierda, Peter Hillmen, John F. Gerecitano, Elisa Cerri, Jalaja Potluri, Su Young Kim, Todd Busman, Maria Verdugo, Rod Humerickhouse, (unknown), Monali Desai, Stephan Stilgenbauer
6
18
Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results
2015 ·Blood ·Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts, Amit B. Agarwal, Thierry Façon, Shaji Kumar, Cyrille Touzeau, (unknown), (unknown), Jeremy A. Ross, Ahmed Hamed Salem, Wijith Munasinghe, Ming Zhu, Joel Johansson, Paulo Maciag, Sari H. Enschede, Maria Verdugo, Rod Humerickhouse, Simon J. Harrison
19
19
Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes
2003 ·British Journal of Haematology ·(unknown), Maria Verdugo, Katherine A. Guthrie, Frederick R. Appelbaum, H. Joachim Deeg
20
20
X‐linked agammaglobulinaemia and squamous lung cancer
2001 ·European Respiratory Journal ·José Echave-Sustaeta, V. Villena, Maria Verdugo, Á. López Encuentra, Pedro de Agustín, N. Alberti
11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mehrdad Mobasher Breakdown of academic impact, for papers by Kathryn Humphrey Breakdown of academic impact, for papers by John N. Allan Breakdown of academic impact, for papers by James D’Rozario Breakdown of academic impact, for papers by Sissy Peterman Breakdown of academic impact, for papers by Virginia Kelly Breakdown of academic impact, for papers by Margaret S. Lucas Breakdown of academic impact, for papers by Stephanie A. Smoley Breakdown of academic impact, for papers by Anna‐Maria Fink Breakdown of academic impact, for papers by Alice Lynn
Rankless by CCL
2026